Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer

Genetic alterations in circulating tumor DNA (ctDNA) are an emerging biomarker for the early detection of relapse and have the potential to guide targeted treatment. ctDNA analysis is often performed by droplet digital PCR; however, next-generation sequencing (NGS) allows multigene testing without h...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Case Rep Oncol Med
Autores principales: Cheng, Fiona Tsui-Fen, Lapke, Nina, Wu, Chin-Chu, Lu, Yen-Jung, Chen, Shu-Jen, Yu, Pei-Ning, Liu, Yen-Ting, Tan, Kien Thiam
Formato: Artigo
Lenguaje:Inglês
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6754891/
https://ncbi.nlm.nih.gov/pubmed/31583146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/6545298
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares